Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Nutritional-GICompleted with results Location: USA
SOLUTION: Study of Liprotamase in people with CF , protocol number NCT00449878 AN-EP13331 - Anthera
This study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of the drug Liprotamase in people with CF who are currently taking digestive enzymes.
Age:
7 Years and Older
Mutation(s):
No Mutation Requirement
FEV1% Predicted:
30% or greater
Number of Visits:
10
Length of Participation:
28 weeks
Nutritional-GIEnrolling Location: USA
SIMPLICITY: Phase 3 study of liprotamase in people with CF-related pancreatic insufficiency , protocol number Anthera AN-EP13332
This two-part study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of a new, water-soluble formulation of liprotamase.
28 Days to 17 Years
No FEV1 Limit
7
24 weeks
Anti-InflammatoryCompleted with results Location: USA
AquADEKs-2: Effects of an antioxidant-enriched multivitamin on inflammation and oxidative stress in people with CF , protocol number AquADECKs-IP-12
This study took place at multiple care centres across the US. It looked at the effects on an anti-oxidant enriched multivitamin supplement on inflammation and oxidative stress in people with CF.
10 Years and Older
40 to 100%
4
20 weeks
ObservationalCompleted with results Location: USA
BONUS: Baby Observational and Nutritional Study , protocol number BONUS-IP-11, BONUS10K0
This study took place at multiple care centres across the US. It aimed to gain a better understanding of the factors that interfere with good growth in infants with CF.
Less than 15 weeks
9
12 months
Anti-InfectiveCompleted with results Location: USA
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis , protocol number Novartis CTBM100C2401
This open-label study assessed the long term safety of tobramycin inhalation powder (TIP) in people with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
6 Years and Older
25 to 75%
52 weeks
Anti-InfectiveClosed to enrollment Location: USA
Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study , protocol number Novartis CTBM100C2401E1
The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".
8
48 weeks
ObservationalEnrolling Location: USA
Phase 4 TOBI Podhaler observational study , protocol number Novartis CTBM100C2407
This study is taking place at multiple care centres across the US. It will look at the effectiveness and long term safety of the TOBI Podhaler and other FDA-approved inhaled antipseudomonal drugs.
25 to 80%
22
60 months
TOBI Podhaler Usability Study , protocol number Novartis CTBM100C2412
This study took place at multiple care centres across the US. It looked at how well people are able to understand and follow the TOBI Podhaler instructions for use.
25% or greater
2
1 month
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered Twice a Day Cycled , protocol number Novartis CTBM100CUS03
This open-label study tested the effectiveness and safety of two different dose regimens of Tobramycin Inhalation Powder (TIP) for the treatment of Pseudomonas aeruginosa.
Anti-InflammatoryEnrolling Location: USA
Phase 2 study of CTX-4430 in people with CF (EMPIRE) , protocol number Celtaxsys CTX-4430
This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug CTX-4430 and will use a placebo control.
18 Years to 30 Years
No Mutation Requirements
50% or greater
15
1 year